Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carolyne Croizier

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Bulletin Du Cancer|November 16, 2018
[Daratumumab for multiple myeloma]Carolyne Croizier, Sébastien Bailly
Bulletin Du Cancer|April 26, 2021
[Richter Syndrome: Diagnostic and Therapeutic Management]Carolyne Croizier, Romain Guièze
Bulletin Du Cancer|September 3, 2024
[Elranatamab monotherapy in multiple myeloma after at least three prior treatments]Erwann Collomb, Carolyne Croizier
Bulletin Du Cancer|June 14, 2024
[Glofitamab in relapsed and/or refractory diffuse large B cell lymphoma after at least two lines of treatment]Valentin Daguerre, Carolyne Croizier
Bulletin Du Cancer|March 27, 2025
[Daratumumab, bortezomib, lenalidomide and dexamethasone in patients treated for multiple myeloma eligible for autologous stem cell transplantation]Minh Quang Pham, Carolyne Croizier
La Revue Du Praticien|June 23, 2025
[Chronic lymphocytic leukaemia]Carolyne Croizier, Romain Guièze, Olivier Tournilhac
Bulletin Du Cancer|January 22, 2022
[New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment]Carolyne Croizier, Zoé Van de Wyngaert
Bulletin Du Cancer|August 19, 2018
[The CAR-T cells are here]Carolyne Croizier, Aurore Douge, Jacques-Olivier Bay, et al.
Bulletin Du Cancer|March 19, 2026
["AMM updates" section of the journal Bulletin du Cancer: Feedback from the contributing authors]Emma Ferber, Carolyne Croizier, Hedi Bensaber, et al.
Psychological Medicine|July 4, 2020
COVID-19 lockdown and mental health: why we must look into oncology unitsCarolyne Croizier, Jean-Baptiste Bouillon-Minois, Jacques-Olivier Bay, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Bulletin Du Cancer|November 16, 2018
[Daratumumab for multiple myeloma]Carolyne Croizier, Sébastien Bailly
Bulletin Du Cancer|April 26, 2021
[Richter Syndrome: Diagnostic and Therapeutic Management]Carolyne Croizier, Romain Guièze
Bulletin Du Cancer|September 3, 2024
[Elranatamab monotherapy in multiple myeloma after at least three prior treatments]Erwann Collomb, Carolyne Croizier
Bulletin Du Cancer|June 14, 2024
[Glofitamab in relapsed and/or refractory diffuse large B cell lymphoma after at least two lines of treatment]Valentin Daguerre, Carolyne Croizier
Bulletin Du Cancer|March 27, 2025
[Daratumumab, bortezomib, lenalidomide and dexamethasone in patients treated for multiple myeloma eligible for autologous stem cell transplantation]Minh Quang Pham, Carolyne Croizier
La Revue Du Praticien|June 23, 2025
[Chronic lymphocytic leukaemia]Carolyne Croizier, Romain Guièze, Olivier Tournilhac
Bulletin Du Cancer|January 22, 2022
[New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment]Carolyne Croizier, Zoé Van de Wyngaert
Bulletin Du Cancer|August 19, 2018
[The CAR-T cells are here]Carolyne Croizier, Aurore Douge, Jacques-Olivier Bay, et al.
Bulletin Du Cancer|March 19, 2026
["AMM updates" section of the journal Bulletin du Cancer: Feedback from the contributing authors]Emma Ferber, Carolyne Croizier, Hedi Bensaber, et al.
Psychological Medicine|July 4, 2020
COVID-19 lockdown and mental health: why we must look into oncology unitsCarolyne Croizier, Jean-Baptiste Bouillon-Minois, Jacques-Olivier Bay, et al.
Pageof 3